PALO ALTO, CA--(Marketwired - Apr 15, 2014) - The 2014 RxTrace 'US Pharma Traceability Survey', sponsored by Frequentz, a leader in comprehensive traceability and information management technologies, is available today for immediate download. The survey, which reveals industry perspectives on the Drug Supply Chain Security Act (DSCSA), can be accessed here: http://frequentz.com/rxtrace-survey-results/.
Enacted in November 2013, DSCSA, which is Title II within the larger Drug Quality and Security Act (DQSA), created new federal track-and-trace requirements for the pharmaceutical supply chain and preempted all state and federal serialization and pedigree laws. RxTrace, a website focused on traceability and the pharmaceutical supply chain, surveyed 78 executives working in, or targeting, the pharmaceutical supply chain to gauge their opinion and state of readiness to comply with DSCSA.
Key findings of the survey revealed:
- Most companies will treat the DSCSA and thus DQSA with the same or more urgency and interest than they treated the California pedigree law
- While most people believe their company leaders understand all or most of what will be required to meet the requirements, uncertainty still exists in many of the definitions of what is required
- Most people agree that EPCIS will be the future technology agreed upon to pass transaction information
Survey questions included:
- What is your interpretation of the Federal DSCSA regarding 'aggregation data' during the first 10 years (Phase I)?
- Will your company request your suppliers to provide 'aggregation data' for some or all shipments?
"Frequentz is taking the lead in supporting customer compliance with, and implementation of, requirements from the Drug Supply Chain Security Act," said Michael Lucas, president and founder, Frequentz. "To that end, we formed a steering committee of customers to collaboratively interpret the recently passed track-and-trace legislation. Our relationship with RxTrace and the sponsorship of the survey supports our goal of educating the industry on the benefits of traceability solutions and to make sure we're all on the same page."
"With the passage of the federal Drug Supply Chain Security Act, companies filling any role in the US supply chain will need to start passing transaction data on each change of ownership as soon as January 1, 2014," said Dirk Rodgers, founder of RxTrace. "The results of this survey offer an important view into the thinking of leading companies in the supply chain, including early interpretations of various components of the new law. I salute Frequentz's efforts to help their partners be ready."
This is the first survey to measure the pharmaceutical industry's thoughts around DQSA. The RxTrace report provides invaluable insight for companies required to comply with the new federal track-and-trace regulations. For more information, please visit: http://frequentz.com/rxtrace-survey-results/.
Frequentz is a leader in comprehensive traceability and information management technologies that improve productivity, product quality, and profitability. Its solutions provide valuable insight into end-to-end supply chains, and critical business processes by collecting, storing and analyzing serialized, life history data. Applications of its software are currently used in the agricultural, fishery and sustainability, life science retail, and automotive industries globally and promotes intelligent analytics and consumer safety.
RxTrace is a comprehensive exploration of the intersection between the pharmaceutical supply chain, track and trace technology, standards and regulatory compliance. Author Dirk Rodgers publishes new, easy to read essays each week that explore issues, concepts and ideas drawn from that intersection. His writing -- suitable for non-technical and technical readers alike -- has helped to expose hidden complexities and reveal surprising consequences and implications of drug serialization and pedigree laws. Subscriptions are free of charge. RxTrace can be found at www.RxTrace.com.
For more information visit: www.frequentz.com, or contact Glen Wellbrock directly at 858.461.4417.